

MEDINEX LIMITED

Incorporated in the Republic of Singapore

Registration No. 200900689W

INVESTMENT IN QUOTED SECURITIES

The Board of Directors (the "**Board**") of Medinex Limited (the "**Company**") refers to the announcement made by the Company on 13 July 2020 in relation to the conversion of the convertible loan into fully paid-up new ordinary shares in Singapore Paincare Holdings Limited ("**SPH**") ("**Announcement**").

Unless otherwise defined, all capitalised terms used herein shall bear the same meanings as ascribed to them in the Announcement.

Further to the Announcement, the Company has applied for and has been allotted 2,248,000 shares in SPH at S\$0.22 per placement share pursuant to SPH's placement in connection with its Proposed Listing. The Board is pleased to announce that SPH has successfully listed on the Catalist board of the Singapore Exchange Securities Trading Limited today (the "**Listing**").

Consequently, with the Listing, the Group's aggregate cost of investment in quoted securities has exceeded multiple of 5% of the Group's audited consolidated net tangible assets ("**NTA**") as at 31 December 2018. Pursuant to Rule 704(16)(b) of the Singapore Exchange Securities Trading Limited Listing Manual Section B: Rules of Catalist, information of the acquisition is as follows:

		Before Acquisition	After Acquisition
(i)	Aggregate cost of the Group's quoted investments (S\$'000)	671	1,916
	Aggregate cost of the Group's quoted investments as a percentage of the latest audited consolidated NTA of the Company as at 31 December 2018 ⁽¹⁾	6.89%	19.66%
(ii)	Total market value of the Group's quoted investments ⁽²⁾ (S\$'000)	639	2,414
(iii)	Amount of any provision for diminution in value of investments (S\$'000)	-	-

Notes:

(1) The audited consolidated NTA of the Group as at 31 December 2018 was S\$9,747,125.

(2) Based on the volume weighted average price of the quoted securities transacted on 30 July 2020, as extracted from Thomson Reuters Eikon.

By Order of the Board

Jessie Low Mui Choo
Executive Director and Chief Executive Officer

30 July 2020

Medinex Limited (the "**Company**") was listed on Catalist of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") on 7 December 2018. The initial public offering of the Company was sponsored by Novus Corporate Finance Pte. Ltd. (the "**Sponsor**").

This announcement has been prepared by the Company and reviewed by the Sponsor, in compliance with Rule 226(2)(b) of the SGX-ST Listing Manual Section B: Rules of Catalist.

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made, or reports contained in this announcement.

The contact person for the Sponsor is Mr. Pong Chen Yih, Chief Operating Officer, at 9 Raffles Place, #17-05 Republic Plaza Tower 1, Singapore 048619, telephone (65) 6950 2188.